palmidrol has been researched along with Nerve Pain in 26 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The management of the associated neuropathic pain remains difficult to treat." | 3.11 | A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. ( Pickering, E; Rao, A; Steadman, KJ; Steels, EL; Vitetta, L, 2022) |
| "gluteus or groin), lumbago with projecting pain to the thigh or leg, pure sciatica and radiculopathy, and investigated any correlations (Spearman) between the improvement in pain and function with these five classes." | 2.90 | Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain - Sciatica. ( Cruccu, G; Marchettini, P; Stefano, GD; Truini, A, 2019) |
| "We randomized 73 individuals with neuropathic pain due to SCI, of which 5 had a major protocol violation, and thus 68 were included in the primary analysis." | 2.82 | Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. ( Andresen, SR; Bach, FW; Biering-Sørensen, F; Bing, J; Finnerup, NB; Hagen, EM; Hansen, RM; Johannesen, IL; Nielsen, JF; Rice, ASC, 2016) |
| "Peripheral neuropathic pain originates from injury to the peripheral nervous system (PNS) and manifests as a series of symptoms and complications, including allodynia and hyperalgesia." | 2.66 | ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. ( Cuzzocrea, S; D'Amico, R; Di Paola, R; Impellizzeri, D, 2020) |
| "Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage or disease of the somatosensory nervous system, and remains largely untreatable." | 2.50 | Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. ( Costa, B; Della Valle, MF; Facci, L; Fusco, M; Giusti, P; Skaper, SD; Zusso, M, 2014) |
| "The mechanisms involved in neuropathic pain are complex and involve both peripheral and central phenomena." | 2.48 | Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. ( Przewlocka, B; Starowicz, K, 2012) |
| "In the current management of neuropathic pain, in addition to antidepressants and anticonvulsants, the use of opioids is wide, despite their related and well-known issues." | 2.44 | Ultramicronized ( Bartolucci, G; Ciampi, C; Di Cesare Mannelli, L; Ferrara, V; Ghelardini, C; Lucarini, E; Micheli, L; Nobili, S; Pallecchi, M; Toti, A, 2024) |
| "Neuropathic pain is a condition caused by a lesion or disease of the somatosensory nervous system." | 1.72 | Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study. ( Kamper, D, 2022) |
| "Patients with neuropathic pain resulting from lumbosciatalgia were assigned to conventional treatment plus PEA or conventional treatment." | 1.42 | Sex differences in N-palmitoylethanolamide effectiveness in neuropathic pain associated with lumbosciatalgia. ( Jaen, A; Morera, C; Sabates, S, 2015) |
| "Neurotoxicity is a main side effect of the anticancer drug oxaliplatin." | 1.42 | Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. ( Boccella, S; Calignano, A; Corti, F; Cuzzocrea, S; Di Cesare Mannelli, L; Esposito, E; Ghelardini, C; Luongo, L; Maione, S; Pacini, A, 2015) |
| "Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels." | 1.39 | Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. ( Cristino, L; De Petrocellis, L; Di Marzo, V; Korostynski, M; Makuch, W; Malek, N; Petrosino, S; Przewlocka, B; Slezak, M; Starowicz, K; Zychowska, M, 2013) |
| "Central neuropathic pain is a common debilitating symptom in patients with multiple sclerosis." | 1.38 | Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. ( Hesselink, JM; Kopsky, DJ, 2012) |
| "Pudendal neuralgia is a cause of chronic, disabling, and often intractable perineal pain presenting as burning, tearing, sharp shooting, foreign body sensation, and it is often associated with multiple, perplexing functional symptoms." | 1.36 | Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. ( Bramanti, P; Calabrò, RS; Gervasi, G; Marino, S; Mondo, PN, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Cristiano, C | 1 |
| Avagliano, C | 1 |
| Cuozzo, M | 1 |
| Liguori, FM | 1 |
| Calignano, A | 2 |
| Russo, R | 1 |
| Pickering, E | 1 |
| Steels, EL | 1 |
| Steadman, KJ | 1 |
| Rao, A | 1 |
| Vitetta, L | 1 |
| Micheli, L | 3 |
| Lucarini, E | 3 |
| Nobili, S | 3 |
| Bartolucci, G | 3 |
| Pallecchi, M | 3 |
| Toti, A | 3 |
| Ferrara, V | 3 |
| Ciampi, C | 3 |
| Ghelardini, C | 4 |
| Di Cesare Mannelli, L | 4 |
| Kiso, T | 1 |
| Watabiki, T | 1 |
| Sekizawa, T | 1 |
| D'Amico, R | 1 |
| Impellizzeri, D | 1 |
| Cuzzocrea, S | 2 |
| Di Paola, R | 1 |
| Parisi, S | 1 |
| Ditto, MC | 1 |
| Borrelli, R | 1 |
| Fusaro, E | 1 |
| Kamper, D | 1 |
| Chirchiglia, D | 1 |
| Paventi, S | 1 |
| Seminara, P | 1 |
| Cione, E | 1 |
| Gallelli, L | 1 |
| Boccella, S | 3 |
| Marabese, I | 2 |
| Iannotta, M | 2 |
| Belardo, C | 2 |
| Neugebauer, V | 1 |
| Mazzitelli, M | 1 |
| Pieretti, G | 1 |
| Maione, S | 4 |
| Palazzo, E | 1 |
| Cruccu, G | 1 |
| Stefano, GD | 1 |
| Marchettini, P | 1 |
| Truini, A | 1 |
| Starowicz, K | 2 |
| Makuch, W | 1 |
| Korostynski, M | 1 |
| Malek, N | 1 |
| Slezak, M | 1 |
| Zychowska, M | 1 |
| Petrosino, S | 1 |
| De Petrocellis, L | 1 |
| Cristino, L | 1 |
| Przewlocka, B | 2 |
| Di Marzo, V | 2 |
| Skaper, SD | 2 |
| Facci, L | 2 |
| Fusco, M | 1 |
| Della Valle, MF | 1 |
| Zusso, M | 1 |
| Costa, B | 2 |
| Giusti, P | 1 |
| Khasabova, IA | 1 |
| Yao, X | 1 |
| Paz, J | 1 |
| Lewandowski, CT | 1 |
| Lindberg, AE | 1 |
| Coicou, L | 1 |
| Burlakova, N | 1 |
| Simone, DA | 1 |
| Seybold, VS | 1 |
| Morera, C | 1 |
| Sabates, S | 1 |
| Jaen, A | 1 |
| Pacini, A | 1 |
| Corti, F | 1 |
| Luongo, L | 3 |
| Esposito, E | 1 |
| Guida, F | 2 |
| Marmo, F | 1 |
| Romano, R | 1 |
| Napolitano, F | 1 |
| D'Aniello, A | 1 |
| De Gregorio, D | 1 |
| Rossi, F | 2 |
| Piscitelli, F | 1 |
| Lattanzi, R | 1 |
| de Bartolomeis, A | 1 |
| Usiello, A | 1 |
| de Novellis, V | 2 |
| Andresen, SR | 1 |
| Bing, J | 1 |
| Hansen, RM | 1 |
| Biering-Sørensen, F | 1 |
| Johannesen, IL | 1 |
| Hagen, EM | 1 |
| Rice, ASC | 1 |
| Nielsen, JF | 1 |
| Bach, FW | 1 |
| Finnerup, NB | 1 |
| Karbarz, MJ | 1 |
| Luo, L | 1 |
| Chang, L | 1 |
| Tham, CS | 1 |
| Palmer, JA | 1 |
| Wilson, SJ | 1 |
| Wennerholm, ML | 1 |
| Brown, SM | 1 |
| Scott, BP | 1 |
| Apodaca, RL | 1 |
| Keith, JM | 1 |
| Wu, J | 1 |
| Breitenbucher, JG | 1 |
| Chaplan, SR | 1 |
| Webb, M | 1 |
| Guasti, L | 1 |
| Richardson, D | 1 |
| Jhaveri, M | 1 |
| Eldeeb, K | 1 |
| Barrett, D | 1 |
| Elphick, MR | 1 |
| Alexander, SP | 1 |
| Kendall, D | 1 |
| Michael, GJ | 1 |
| Chapman, V | 1 |
| Calabrò, RS | 1 |
| Gervasi, G | 1 |
| Marino, S | 1 |
| Mondo, PN | 1 |
| Bramanti, P | 1 |
| Kopsky, DJ | 2 |
| Hesselink, JM | 2 |
| Bettoni, I | 1 |
| Comelli, F | 1 |
| Colombo, A | 1 |
| Bonfanti, P | 1 |
| Bellini, G | 1 |
| Gatta, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Postoperative Pain and Inflammation Following Below Knee Fracture Fixation: A Pilot Study.[NCT05317676] | Phase 2 | 0 participants (Actual) | Interventional | 2023-05-31 | Withdrawn (stopped due to Sponsor suspending temporarily.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for palmidrol and Nerve Pain
| Article | Year |
|---|---|
ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.
Topics: Amides; Analgesics; Anti-Inflammatory Agents; Ethanolamines; Humans; Neuralgia; Palmitic Acids | 2020 |
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Topics: Amides; Animals; Endocannabinoids; Ethanolamines; Humans; Inflammation; Mast Cells; Neuralgia; Neuro | 2014 |
Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acid; Arachidonic Acids; Behavior; Benzamides; Carbama | 2012 |
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.
Topics: Amides; Animals; Cell Communication; Central Nervous System; Endocannabinoids; Ethanolamines; Humans | 2012 |
4 trials available for palmidrol and Nerve Pain
| Article | Year |
|---|---|
A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain.
Topics: Australia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Inflammation; Neuralgia; Treatm | 2022 |
N-Palmitoyl Ethanol Amide Pharmacological Treatment in Patients With Nonsurgical Lumbar Radiculopathy.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amides; Codeine; Drug Combinations; Ethanolamines; Fe | 2018 |
Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain - Sciatica.
Topics: Adult; Amides; Cohort Studies; Ethanolamines; Female; Humans; Low Back Pain; Male; Middle Aged; Neur | 2019 |
Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amides; Analgesics; Analysis of Variance; Double-Blind Method; Ethanolamines; Female; F | 2016 |
18 other studies available for palmidrol and Nerve Pain
| Article | Year |
|---|---|
The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice.
Topics: Amides; Animals; Endocannabinoids; Ethanolamines; Mice; Neuralgia; Paclitaxel; Palmitic Acids; PPAR | 2022 |
Ultramicronized
Topics: Analgesics, Opioid; Animals; Histamine; Mast Cells; Morphine; Neuralgia; Neuroglia; Rats | 2024 |
Ultramicronized
Topics: Analgesics, Opioid; Animals; Histamine; Mast Cells; Morphine; Neuralgia; Neuroglia; Rats | 2024 |
Ultramicronized
Topics: Analgesics, Opioid; Animals; Histamine; Mast Cells; Morphine; Neuralgia; Neuroglia; Rats | 2024 |
Ultramicronized
Topics: Analgesics, Opioid; Animals; Histamine; Mast Cells; Morphine; Neuralgia; Neuroglia; Rats | 2024 |
ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Behavior, Animal; Brain; Chronic Pain; Disease Models, | 2020 |
Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases.
Topics: Acetylcarnitine; Aged; Amides; Analgesics, Non-Narcotic; Carpal Tunnel Syndrome; Drug Administration | 2021 |
Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study.
Topics: Aged; Amides; Ethanolamines; Herpes Zoster; Humans; Male; Neuralgia; Palmitic Acids; Pisum sativum; | 2022 |
Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain.
Topics: Amides; Animals; Dentate Gyrus; Disease Models, Animal; Ethanolamines; Excitatory Postsynaptic Poten | 2019 |
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Topics: Amides; Amidohydrolases; Analgesia; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Benzam | 2013 |
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
Topics: Amides; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cells, Culture | 2014 |
Sex differences in N-palmitoylethanolamide effectiveness in neuropathic pain associated with lumbosciatalgia.
Topics: Adult; Aged; Amides; Analgesics; Ethanolamines; Female; Humans; Low Back Pain; Lumbosacral Region; M | 2015 |
Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity.
Topics: Activating Transcription Factor 3; Amides; Animals; Behavior, Animal; Disease Models, Animal; Ethano | 2015 |
Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice.
Topics: Amides; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cells, Cultured; Electrophysio | 2015 |
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Brain; Carrageenan; Disease Models, | 2009 |
Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain.
Topics: Amides; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cell Proliferation; Disease Mod | 2009 |
Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide.
Topics: Adult; Amides; Analgesics; Animals; Diagnostic Errors; Endocannabinoids; Ethanolamines; Humans; Male | 2010 |
Nerve regeneration in neuropathic pain.
Topics: Acetylcarnitine; Amides; Endocannabinoids; Ethanolamines; Humans; Nerve Regeneration; Neuralgia; Noo | 2010 |
Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain.
Topics: Acupuncture Therapy; Amides; Analgesia; Analgesics; Chronic Disease; Endocannabinoids; Ethanolamines | 2012 |
Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.
Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Male; Mast Cells; Mice; Mice, Inbred C | 2013 |
Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice.
Topics: Action Potentials; Amides; Animals; Endocannabinoids; Ethanolamines; Formaldehyde; Male; Mice; Mice, | 2013 |